Stephanie Dellicour is a Senior Lecturer at Liverpool School of Tropical Medicine (LSTM), specialising in advancing methodologies for assessing the benefits and risks of therapeutics during pregnancy, particularly in resource-limited settings. With 20 years of experience in epidemiology, pharmacovigilance, and global health research, her work aims to strengthen evidence for informed policy decisions, ensuring that pregnant patients and healthcare providers have access to critical information for decision-making. Her work is guided by four years as a visiting scientist at the Kenya Medical Research Institute in western Kenya, as well as previous roles in the pharmaceutical industry and the UK drug regulatory agency.

Stephanie leads the Malaria in Mothers and Babies Pregnancy Exposure Registry, an international collaboration and multicentre active surveillance project designed to evaluate the safety of antimalarials during pregnancy. She is also the project lead for the SAFIRE consortium at LSTM, which involves the first adaptive platform trial designed to assess malaria treatments during the first trimester of pregnancy in Africa.

Stephanie's research focuses on the safety assessment of medications used during pregnancy, with a particular emphasis on antimalarial treatments in resource-limited settings. She has led evidence-synthesis efforts on artemisinin-based therapies in early pregnancy to inform World Health Organisation treatment guidelines. Her work in pharmacoepidemiology bridges the gap between clinical research, pharmacovigilance, and public health policy implementation.

Key areas of her research include, developing and implementing observational studies to monitor medication safety in pregnancy, investigating the burden and impact of malaria infection during pregnancy, evaluating healthcare provider adherence to malaria treatment guidelines for pregnant patients, and novel trial approaches for ethical and safe inclusion of pregnant participants.